PITTSBURGH and POTTERS BAR, England, Oct. 25, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.K.-based subsidiary has launched Rivastigmine Capsules POM, 1.5 mg, 3 mg, 4.5 mg and 6 mg. This product is the generic version of Novartis' Exelon® Capsules, a treatment for dementia in people with Alzheimer's disease. Mylan is the first company to launch a generic Rivastigmine formulation in the U.K.
Mylan Chairman and CEO Robert J. Coury said: "This is the second recent first-to-market generic for Mylan's business in the U.K., following the company's successful launch of Modafinil tablets, 100 mg, the generic version of Cephalon's Provigil®, earlier this year. We are excited to be adding generic Rivastigmine to our strong portfolio of more than 350 products in the U.K., and delivering on our brand's commitment of providing high quality and affordable medicines to patients around the world."
Rivastigmine Capsules POM had U.K. sales of approximately pounds Sterling 7.9 million for the last 12 months ending June 30, 2011, according to IMS Health.
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com.
|SOURCE Mylan Inc.|
Copyright©2010 PR Newswire.
All rights reserved